Supporting COVID-19 vaccine & therapeutics development

The unprecedented COVID-19 pandemic and its impact on public health as well as social and economic life worldwide, has created an urgent and pressing need for the development of therapeutics, vaccines and accurate diagnostic tests to combat the disease.

Biogazelle has been at the first line of the fight against COVID-19 on a national level, through our participation in a Belgian government-led consortium of academia, biotech and pharma aimed at dramatically increasing the testing capacity for SARS-CoV-2 in Belgium. In a record time of 2 weeks Biogazelle was able to put in place and validate a RT-qPCR workflow for high-throughput SARS-CoV-2 testing and now serves as one of the official testing centers for the disease in Belgium.

Biogazelle is an expert in RNA and RT-qPCR

Biogazelle’s selection as a partner in this consortium, along the likes of J&J, GSK and UCB, is a recognition of our leadership position in RNA research and RNA biomarker development, our expertise with liquid biopsies as well as our successful track record in carrying through challenging, customized pre-clinical and clinical projects for our clients. Additionally, Biogazelle’s founders Prof Jo Vandesompele and Dr Jan Hellemans are authors of landmark papers in the field of RT-qPCR as well as digital PCR-based gene expression analysis, being cited more than 20,000 times.

How we can help your COVID-19 vaccine or drug pipeline

  • GCLP-compliant, high-throughput diagnostic testing services for SARS-CoV-2 in an ISO17025 environment
  • Absolute quantification of viral load through digital PCR
  • High-throughput RNA expression profiling of therapeutic candidates to elucidate effects on cellular pathways and provide insights on potential toxicity
  • RNA biomarker analysis in clinical trial samples

To find out more details on how our experts can help you, or to schedule a call with us, please provide a few details on your project using the form below.

Subscribe to email updates